These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 9129786)

  • 1. Changes in symptoms and plasma homovanillic acid with amantadine hydrochloride in chronic schizophrenia.
    Yamada K; Kanba S; Ohnishi K; Ashikari I; Yagi G; Asai M
    Biol Psychiatry; 1997 May; 41(10):1062-4. PubMed ID: 9129786
    [No Abstract]   [Full Text] [Related]  

  • 2. No difference in the effect of biperiden and amantadine on negative symptoms in medicated chronic schizophrenic patients.
    Silver H; Geraisy N
    Biol Psychiatry; 1995 Sep; 38(6):413-5. PubMed ID: 8547463
    [No Abstract]   [Full Text] [Related]  

  • 3. Negative symptoms in nondeficit syndrome respond to neuroleptic treatment with changes in plasma homovanillic acid concentrations.
    Suzuki E; Kanba S; Koshikawa H; Nibuya M; Yagi G; Asai M
    J Psychiatry Neurosci; 1996 May; 21(3):167-71. PubMed ID: 8935328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Exacerbation of catatonic symptoms in neuroleptic therapy].
    Bräunig P; Krüger S; Höffler J
    Nervenarzt; 1995 May; 66(5):379-82. PubMed ID: 7609820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma HVA, tardive dyskinesia and psychotic symptoms in long-term drug-free inpatients with schizophrenia.
    Muscettola G; Barbato G; de Bartolomeis A; Monteleone P; Pickar D
    Psychiatry Res; 1990 Sep; 33(3):259-67. PubMed ID: 2243901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Schizophrenia and severe tardive dyskinesia responsive to risperidone.
    Kopala LC; Honer WG
    J Clin Psychopharmacol; 1994 Dec; 14(6):430-1. PubMed ID: 7533794
    [No Abstract]   [Full Text] [Related]  

  • 7. Plasma prolactin and homovanillic acid as markers for psychopathology and abnormal movements during maintenance haloperidol treatment in male patients with schizophrenia.
    Newcomer JW; Riney SJ; Vinogradov S; Csernansky JG
    Psychiatry Res; 1992 Mar; 41(3):191-202. PubMed ID: 1594706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coadministration of fluvoxamine increases serum concentrations of haloperidol.
    Daniel DG; Randolph C; Jaskiw G; Handel S; Williams T; Abi-Dargham A; Shoaf S; Egan M; Elkashef A; Liboff S
    J Clin Psychopharmacol; 1994 Oct; 14(5):340-3. PubMed ID: 7806690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma prolactin and homovanillic acid as markers for psychopathology and abnormal movements after neuroleptic dose decrease.
    Newcomer JW; Riney SJ; Vinogradov S; Csernansky JG
    Psychopharmacol Bull; 1992; 28(1):101-7. PubMed ID: 1609034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New use for an old drug: amantadine benefits levodopa-induced dyskinesia.
    Rajput AH; Rajput A; Lang AE; Kumar R; Uitti RJ; Galvez-Jimenez N
    Mov Disord; 1998 Sep; 13(5):851. PubMed ID: 9756161
    [No Abstract]   [Full Text] [Related]  

  • 11. Preliminary investigation of high-dose oral glycine on serum levels and negative symptoms in schizophrenia: an open-label trial.
    Leiderman E; Zylberman I; Zukin SR; Cooper TB; Javitt DC
    Biol Psychiatry; 1996 Feb; 39(3):213-5. PubMed ID: 8837983
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of repeated drug holidays on serum haloperidol concentrations, psychiatric symptoms, and movement disorders in schizophrenic patients.
    Newton JE; Cannon DJ; Couch L; Fody EP; McMillan DE; Metzer WS; Paige SR; Reid GM; Summers BN
    J Clin Psychiatry; 1989 Apr; 50(4):132-5. PubMed ID: 2925601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma HVA in psychiatric patients: longitudinal studies.
    Javaid JI; Sharma RP; Janicak PG; Davis JM
    Psychopharmacol Bull; 1990; 26(3):361-5. PubMed ID: 2274637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Palliative treatment of tardive dyskinesia with combination of amantadine-neuroleptic administration.
    Allen RM
    Biol Psychiatry; 1982 Jun; 17(6):719-27. PubMed ID: 6179548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Negative symptoms: relationship to other schizophrenic symptom classes.
    McKenna PJ; Lund CE; Mortimer AM
    Br J Psychiatry Suppl; 1989 Nov; (7):104-7. PubMed ID: 2619978
    [No Abstract]   [Full Text] [Related]  

  • 16. Replacement of chronically administered anticholinergic drugs by amantadine in outpatient management of chronic schizophrenia.
    McEvoy JP; McCue M; Freter S
    Clin Ther; 1987; 9(4):429-33. PubMed ID: 2886223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical findings. Abnormalities of the mental state and movement disorder and their correlates.
    Johnstone EC; Owens DG; Frith CD; Leary J
    Br J Psychiatry Suppl; 1991 Oct; (13):21-5, 44-6. PubMed ID: 1688117
    [No Abstract]   [Full Text] [Related]  

  • 18. The effect of OPC-4392, a partial dopamine receptor agonist on negative symptoms: results of an open study.
    Gerbaldo H; Demisch L; Lehmann CO; Bochnik J
    Pharmacopsychiatry; 1988 Nov; 21(6):387-8. PubMed ID: 2907646
    [No Abstract]   [Full Text] [Related]  

  • 19. Therapeutic drug monitoring for optimizing amisulpride therapy in patients with schizophrenia.
    Müller MJ; Regenbogen B; Härtter S; Eich FX; Hiemke C
    J Psychiatr Res; 2007 Oct; 41(8):673-9. PubMed ID: 16324716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma homovanillic acid levels in schizophrenic patients: correlation with negative symptoms.
    Dávila R; Zumárraga M; Basterreche N; Arrúe A; Anguiano JB
    Psychiatry Res; 2007 May; 151(1-2):163-8. PubMed ID: 17434602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.